Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
about
Japanese encephalitis: the virus and vaccinesTick-Borne Encephalitis Virus Structural Proteins Are the Primary Viral Determinants of Non-Viraemic Transmission between Ticks whereas Non-Structural Proteins Affect CytotoxicityChimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile VirusNeuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular cloneAttenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient miceSingle mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulenceA live, attenuated recombinant West Nile virus vaccine.JE Nakayama/JE SA14-14-2 virus structural region intertypic viruses: Biological properties in the mouse model of neuroinvasive diseaseDengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine DevelopmentNeuroadapted Yellow Fever Virus 17D: Determinants in the Envelope Protein Govern Neuroinvasiveness for SCID MiceTNF-α promoter polymorphism: a factor contributing to the different immunological and clinical phenotypes in Japanese encephalitis.Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability.A molecularly cloned, live-attenuated japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the ij Hairpin of the Viral E glycoprotein determines neurovirulence in miceDengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in miceChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.Recent advancement in flavivirus vaccine development.Exploring Genomic, Geographic and Virulence Interactions among Epidemic and Non-Epidemic St. Louis Encephalitis Virus (Flavivirus) StrainsGenetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in MiceYellow fever vaccine.Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessmentJapanese encephalitis: development of new candidate vaccines.Pathogenic and Genotypic Characterization of a Japanese Encephalitis Virus Isolate Associated with Reproductive Failure in an Indian Pig Herd.Rational design of a flavivirus vaccine by abolishing viral RNA 2'-O methylation.Current use and development of vaccines for Japanese encephalitis.Biomarkers in Japanese encephalitis: a review.Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.Envelope Protein Mutations L107F and E138K Are Important for Neurovirulence Attenuation for Japanese Encephalitis Virus SA14-14-2 Strain.Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Biological and genetic properties of SA₁₄-14-2, a live-attenuated Japanese encephalitis vaccine that is currently available for humans.Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain.Pathogenic and vaccine strains of Japanese encephalitis virus elicit different levels of human macrophage effector functions.Japanese B Encephalitis: An Overview of the Disease and Use of Chimerivax-JE as a Preventative Vaccine.Molecular basis for adaptation of a chimeric dengue type-4/Japanese encephalitis virus to Vero cells.Complete genome sequence analysis of Japanese encephalitis virus isolated from a horse in India.African and Asian Zika Virus Isolates Display Phenotypic Differences Both In Vitro and In Vivo.
P2860
Q27010434-BA9A24B3-7337-43F7-8267-F29815946A30Q27469029-4F62DB89-09CC-4F03-BAA9-F7668D5BEA4EQ27469831-D14E8575-8DF9-4F19-AEB8-CD937BFB0DCFQ27469879-20EF4BA2-6AD8-4736-A277-36E3798FE5BBQ27469932-77FFC08C-D31A-41F2-94A4-28771F927352Q27472824-D7CADAE1-E838-4419-9813-BFDCA13B0A7EQ27472841-515C549D-0A4D-428F-A2DC-A49FD56A4FA4Q27472855-57ED02C2-ECE7-49D6-B90F-5B3E7A996D36Q27473138-43E68810-155D-4176-A4FA-6E1033B43557Q27485478-707C1A6B-2A68-40FB-B968-356601FA7A9AQ27485759-A363DFB7-FF3B-4FBB-BB1A-380E718335FFQ27486896-0DD43DF1-E554-446A-8A1B-91F321034113Q31046470-B7A2082B-9ED6-4F39-9DF6-3AD05A7994E4Q33687913-5EDF1FD7-CB81-4A50-BC3A-C259A6E367A3Q33982616-9A963769-3096-49AA-B18D-A1CD7BF748BDQ34066921-0FEC926B-8DF0-4978-8571-9C25F5E446FDQ34362322-9F4CB6A2-0E3A-413C-830B-555BC8808430Q35140658-3D03FD85-FC98-48B4-AB5F-68A07658176AQ35728621-AEA1CD93-27EE-4731-8629-AB3A88FCCA4DQ35757086-68ECD5AE-5508-4CF8-A913-45865D6CFD6BQ35760499-FA54D27B-7C11-4C86-89C7-06C18D46EFA1Q36238729-5094166D-69F5-4032-A05E-995733D27E7FQ36307457-C4F53A8D-6969-44DB-B594-121C59699048Q36441519-A83A2A07-335F-488F-A675-8CCB8CFDC975Q36599411-4958D5BB-64BC-4AF1-810A-C36164CB4E6CQ36827340-E18C1C81-742D-4651-997B-3E45AEC0B92AQ37032646-EAFFD747-6520-4E85-9D3D-7CB994AF415BQ37425963-1C79C164-15E8-4C59-AC3D-A5180D355BF1Q37596501-080BE2A5-3339-4BC3-BDCE-8218590A259CQ37628229-DDDE7CBC-9C6A-4FE9-8387-BE66768F7036Q37666763-4BCD8C38-8673-4015-9D86-263189D3A71EQ37812123-7A63939B-7F8A-4221-A3B5-DEA059D56F95Q39181962-6FEB4543-F7B0-4A4D-A045-6A888846959EQ39290828-F8ACB384-70AC-4DEA-8E6F-FF33F64B3FD9Q39311849-6BE6A997-4F2A-49DD-B576-1560D3E99D96Q39325923-3690EB42-82B2-4502-8010-F1DEC3F85B78Q40196301-6977EB1B-8EB1-4A54-A2C6-B6D23062653EQ40443996-C901CB1F-5090-4B61-9279-E336BFD82654Q42984425-46A8D2E1-1966-493E-9AFF-52FD492F3010Q47244845-35E6D3C0-7DA6-4E8A-831F-41CF7D0311AA
P2860
Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Molecular Basis for Attenuatio ...... himera Vaccine (ChimeriVax-JE)
@nl
Molecular basis for attenuatio ...... imera vaccine (ChimeriVax-JE).
@ast
Molecular basis for attenuatio ...... imera vaccine (ChimeriVax-JE).
@en
type
label
Molecular Basis for Attenuatio ...... himera Vaccine (ChimeriVax-JE)
@nl
Molecular basis for attenuatio ...... imera vaccine (ChimeriVax-JE).
@ast
Molecular basis for attenuatio ...... imera vaccine (ChimeriVax-JE).
@en
prefLabel
Molecular Basis for Attenuatio ...... himera Vaccine (ChimeriVax-JE)
@nl
Molecular basis for attenuatio ...... imera vaccine (ChimeriVax-JE).
@ast
Molecular basis for attenuatio ...... imera vaccine (ChimeriVax-JE).
@en
P2093
P2860
P921
P3181
P1433
P1476
Molecular basis for attenuatio ...... imera vaccine (ChimeriVax-JE).
@en
P2093
P2860
P304
P3181
P356
10.1128/JVI.75.2.934-942.2001
P577
2001-01-01T00:00:00Z